Bigbear Pharmaceutical·Medication Guide

• How to Alleviate the Side Effects of Selinexor

  Selinexor is a novel targeted anticancer drug that has shown significant efficacy in treating multiple myeloma and diffuse large B-cell lymphoma, but ···【Read More】

  Update: 2026-04-17Source: Haiou HealthViews: 130

• Side Effects and Precautions of Celinixol

  selinexor is a drug used to treat multiple myeloma and diffuse large B-cell lymphoma. It works by inhibiting the XPO1 target. While it has shown signi···【Read More】

  Update: 2026-04-16Source: Haiou HealthViews: 125

• Xpovio (selinexor) Receives Second Oncology Approval: Large B-Cell Lymphoma (DLBCL)

  Karyopharm Therapeutics, a partner of Antengene, recently announced that the U.S. Food and Drug Administration (FDA) has approved Xpovio (selinexor) f···【Read More】

  Update: 2026-04-15Source: Haiou HealthViews: 133

• Xpovio (selinexor) Receives FDA Approval for Third Indication: Treatment of Multiple Myeloma in Patients Receiving at Least One Prior Therapy

  Karyopharm Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) ···【Read More】

  Update: 2026-04-15Source: Haiou HealthViews: 125

• Xpovio (selinexor), a novel oral drug for multiple myeloma, is nearing EU approval and is under review in China!

  Karyopharm Therapeutics recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has is···【Read More】

  Update: 2026-04-15Source: Haiou HealthViews: 139

• Nexpovio (selinexor) Approved in the EU, Marketing Authorization Application Accepted by China's National Medical Products Administration

  Karyopharm Therapeutics recently announced that the European Commission (EC) has conditionally approved Nexpovio (selinexor), in combination with dexa···【Read More】

  Update: 2026-04-15Source: Haiou HealthViews: 141

• The European Commission has granted full marketing authorization to selinexor (Nexpovio) in combination therapy

  The European Commission has granted full marketing authorization to selinexor (Nexpovio) in combination with once-weekly bortezomib (Velcade) and low-···【Read More】

  Update: 2026-04-15Source: Haiou HealthViews: 150

• What other medications may interact with ruxolitinib?

  Be sure to inform your healthcare provider about all medications you are using, including prescription drugs, over-the-counter products, vitamins, and···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 118

• What if I take too much?

  If you accidentally take more ruxolitinib than prescribed, contact your healthcare provider immediately or go to the closest hospital emergency room r···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 118

• What if I forget a dose of Ruxolitinib ?

  If you miss a dose of ruxolitinib, simply take your next scheduled dose at your usual time. Do not double up to make up for the missed dose.【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 125

• Jakafi (Ruxolitinib) Cost With vs. Without Insurance: Out-of-Pocket Breakdown

  The price of ruxolitinib varies depending on the strength, dosage form, region, and purchase channel. Currently, the price of tablets (e.g., 5mg x 28 ···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 134

• How Much Does Ruxolitinib (Jakafi) Cost Per Month? 2026 Price Guide

  The price of ruxolitinib (Ruxolitinib) is significantly affected by dosage, region, and purchase channel, and must be used as prescribed by a doctor. ···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 127

• Jakavi has been approved by the European Commission

  GvHD is a common and potentially life-threatening complication, occurring in approximately half of allogeneic stem cell transplants.On May 5, 2022, No···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 136

• ​The European Commission has recommended the approval of ruxolitinib (Jakafi)

  Recently, the European Medicines Agency's Committee on Medical Products for Human Use recommended the approval of ruxolitinib (Jakafi) for the tre···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 131

• Treatment of Non-Segmental Vitiligo with Facial Affectation in Individuals Aged 12 and Older!

  According to a press release from Incyte on April 20, the European Commission (EC) announced that it has granted marketing authorization to Opzelura 1···【Read More】

  Update: 2026-04-10Source: Haiou HealthViews: 123